Psoriatic arthritis is a form of chronic inflammatory arthritis which affects the toes and fingers of the patient, gradually moving to skin and nails. While the clinical symptoms vary, the most commonly recognized symptoms of psoriatic arthritis are enthesitis, axial disease, peripheral arthritis, and dactylitis.
The global Psoriatic Arthritis Pharmacotherapy Market can be segmented on the basis of region, method, and drug. By method of diagnosis, the global market for psoriatic arthritis pharmacotherapy can be segmented into laboratory tests and imaging. Based on drug type, the market can be categorized into NSAIDs, disease modifying anti-rheumatic drugs (DMARDs), TNF-α inhibitors, and immunosuppressants.
The research report on the global market for psoriatic arthritis pharmacotherapy analyzes the numerous factors limiting and promoting the growth of the market. The major trends observed in the market have been discussed, alongside the recent technological breakthroughs marking the progress of the market. The prominent market players transacting in the global market for psoriatic arthritis pharmacotherapy have been evaluated under the chapter on competitive landscape.
Request to View Brochure of Report -
The rising number of elderly people across the globe has been one of the prime market catalysts. As aging increases the risk of psoriatic arthritis, the global demand for psoriatic arthritis pharmacotherapy is augmenting. The market will also benefit significantly from the introduction of blockbuster drugs including Vicodin and Simponi, apart from several other medications that are presently in the pipeline.
On the flip side, the global market for psoriatic arthritis pharmacotherapy might face challenges owing to the high costs of the newly launched biologics. Along with this market restraint, low level of awareness as to the benefits of psoriatic arthritis pharmacotherapy has also been inhibiting growth.
A study conducted by the Centers for Disease Control and Prevention (CDC), a key national public health organization in the U.S., reveals that the larger portion of patients suffering from psoriatic arthritis did not take the symptoms seriously, ignoring the initial signs such as skin rashes and reddening. Only 10-12% of the patients in the U.S. opted for a diagnosis. In order to combat the prevailing lack of awareness several entities such as Celgene and National Psoriasis Foundation have been striving to create awareness among the people.
Comments
Post a Comment